PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C

被引：0
作者：
Ideo, G
Giuseppe, S
Attili, A
Chirianni, A
Craxi, A
Di Perri, G
Picciotto, A
Rizzetto, M
Ruggiero, G
Suter, F
Sarracino, M
机构：
[1] Osped S Giuseppe, Dept Hepatol, Milan, Italy
[2] Univ Roma La Sapienza, Dept Gastroenterol, Rome, Italy
[3] Cotugno Hosp, Dept Infectious, Naples, Italy
[4] Univ Palermo, Dept Gastroenterol, Palermo, Italy
[5] Savoia Hosp, Dept Infect Amedeo, Turin, Italy
[6] Hepatitis Diagnosis & Therapy, Genoa, Italy
[7] Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, I-10126 Turin, Italy
[8] Univ Naples, Dept Med & Hepatol, Naples, Italy
[9] Spedali Riumti, Dept Infect Dis, Bergamo, Italy
[10] Roche SPA, Monza, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1630
引用
收藏
页码：570A / 570A
页数：1
相关论文
共 50 条
[31]   A comparison of cost effectiveness of peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC) [J].
Sullivan, SD ;
Green, J ;
Patel, KK ;
Crtaxi, A ;
Alberti, A ;
Giuliani, G ;
De Carli, C .
JOURNAL OF HEPATOLOGY, 2003, 38 :174-175
[32]   Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC) [J].
Bruno, R ;
Sacchi, P ;
Ciappina, V ;
Maffezzini, E ;
Patruno, SFA ;
Zocchetti, C ;
Filice, G .
JOURNAL OF HEPATOLOGY, 2003, 38 :129-130
[33]   Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C. [J].
Jensen, CDM ;
Bernstein, DE ;
Hassanein, TI ;
Foster, GR ;
Lee, SS ;
Cheinquer, H ;
Craxi, A ;
Cooksley, WGE ;
Klaskala, W ;
Green, J .
HEPATOLOGY, 2002, 36 (04) :603A-603A
[34]   Predictive factors in treatment of chronic hepatitis c (cHC) patients with peginterferon alfa-2a (40KD) and ribavirin [J].
Zehnter, Elmar ;
Mauss, Stefan ;
John, Christine ;
Heyne, Renate ;
Moeller, Berrid ;
Lutz, Thomas ;
Bokemeyer, Bernd ;
Kihn, Robert ;
Moog, Gero ;
Vornkahl, Heike ;
Alshuth, Ulrich ;
Hueppe, Dietrich .
GASTROENTEROLOGY, 2006, 130 (04) :A839-A839
[35]   Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use [J].
Zehnter, Elmar ;
Mauss, Stefan ;
John, Christine ;
Heyne, Renate ;
Moeller, Bernd ;
Lutz, Thomas ;
Bokemeyer, Bernd ;
Kihn, Robert ;
Moog, Gero ;
Vornkahl, Heike ;
Alshuth, Ulrich ;
Hueppe, Dietrich .
GASTROENTEROLOGY, 2006, 130 (04) :A840-A840
[36]   An evaluation of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for the first treatment of mild chronic hepatitis C (CHC) [J].
Hornberger, J ;
Dusheiko, G ;
Lewis, G ;
Patel, K .
HEPATOLOGY, 2005, 42 (04) :653A-653A
[37]   Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) [J].
Balan, V ;
Zeuzem, S ;
Sette, H ;
Fried, M ;
Jensen, D ;
Pastore, G ;
Marcellin, P ;
Sedarati, F .
JOURNAL OF HEPATOLOGY, 2003, 38 :19-19
[38]   Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin [J].
Snoeck, Eric ;
Wade, Janet R. ;
Duff, Frank ;
Lamb, Matthew ;
Jorga, Karin .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) :699-709
[39]   Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients [J].
Nelson, David R. ;
Zeuzem, Stefan ;
Andreone, Pietro ;
Ferenci, Peter ;
Herring, Robert ;
Jensen, Donald M. ;
Marcellin, Patrick ;
Pockros, Paul J. ;
Rodriguez-Torres, Maribel ;
Rossaro, Lorenzo ;
Rustgi, Vinod K. ;
Sepe, Thomas ;
Sulkowski, Mark ;
Thomason, Isaac R. ;
Yoshida, Eric M. ;
Chan, Anna ;
Hill, George .
ANNALS OF HEPATOLOGY, 2012, 11 (01) :15-31
[40]   PEG-IFN alfa-2a plus ribavirin is superior compared to high dose consensus interferon (CIFN) and ribavirin in the treatment of patients with chronic hepatitis C [J].
Witthoeft, T. ;
Fuchs, M. .
JOURNAL OF HEPATOLOGY, 2007, 46 :S248-S248
12345